PTC Therapeutics posts Q3 2026 results, raises full‑year revenue guidance and announces Fabry gene therapy acquisition
PTC Therapeutics reported third‑quarter 2026 revenue of $358 million and a net loss of $51.7 million. The company lifted its full‑year 2026 revenue outlook to $1.29‑$1.32 billion, driven by strong Sephience sales, and disclosed the $111 million acquisition of the ST‑920 Fabry disease gene therapy with a planned launch in 2027. CEO Matthew Klein noted over 2,000 patients on Sephience and a cash balance of $2.13 billion.
Why it matters
The raised full‑year revenue guidance signals higher top‑line growth than previously expected, which the company says improves its path to cash‑flow breakeven. The ST‑920 acquisition adds a pipeline asset that the company expects could be accretive in 2027. The strong cash position gives flexibility for further business development.
Key facts
- 1Q3 2026 total revenue was $358 million, including $276 million of product revenue. prnewswire.com
- 2Full‑year 2026 total revenue guidance was raised to $1.29‑$1.32 billion, with product revenue guidance $960‑$990 million. prnewswire.com
- 3Sephience generated $182 million in Q3 2026 revenue. prnewswire.com
- 4PTC acquired the ST‑920 Fabry disease gene therapy for $111.0 million upfront, with up to $100.0 million in contingent milestones. prnewswire.com
- 5Net loss for Q3 2026 was $51.7 million. prnewswire.com
- 6Cash, cash equivalents and marketable securities totaled $2,127.9 million as of September 30, 2026. prnewswire.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.